Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  vismodegib
Find trials that include:  Any drugs shown
Results 1-11 of 11 for your search:
Start Over
Vismodegib in Treating Patients with Orbital or Periocular Basal Cell Carcinoma
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2014.022, NCI-2015-00927, ML29160, NCT02436408
A Study of Two Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MO28295, NCI-2013-01423, 2012-003305-10, NCT01815840
Radiation Therapy and Vismodegib in Treating Patients With Locally Advanced Head and Neck Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CC #122011, NCI-2013-00871, 122011, NCT01835626
A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf, and Erivedge Treatment Targeted Against Certain Mutations in Cancer Patients
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ML28897, NCI-2014-01811, NCT02091141
Vismodegib in Preventing Newly Diagnosed Basal Cell Carcinoma in High Risk Patients
Phase: Phase II
Type: Prevention
Age: 18 and over
Trial IDs: 1401183410, NCI-2015-01240, 1401183410R001, NCT02067104
Sirolimus and Vismodegib in Treatment of Patients with Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: MC1111, NCI-2011-03809, NCT01537107
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
Phase: No phase specified
Type: Natural history/Epidemiology
Age: 18 and over
Trial IDs: ML28296, NCI-2013-02254, NCT01604252
Clinical and Molecular Risk-Directed Craniospinal Irradiation and Combination Chemotherapy in Treating Younger Patients with Newly Diagnosed Medulloblastoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 21 at diagnosis
Trial IDs: SJMB12, NCI-2013-01125, NCT01878617
Levocarnitine in Treating Patients with Vismodegib-Associated Muscle Spasms
Phase: No phase specified
Type: Supportive care
Age: 18 and over
Trial IDs: SKIN0018, NCI-2013-01269, 5136, IRB-27478, NCT01893892
Vismodegib in Treating Patients with Hormone-Resistant Metastatic Prostate cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J1423, NCI-2014-02512, Vismodegib, NCT02115828
Vismodegib in Treating Patients with Steroid-Refractory Chronic Graft-versus-Host Disease
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Supportive care
Age: 13 and over
Trial IDs: 9664, NCI-2014-02672, NCT02337517
Start Over